✦ LIBER ✦

Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy

✍ Scribed by Silvia Romero; Gail Stanton; Joseph DeFelice; Fred Schreiber; Randy Rago; Mayer Fishman

Book ID: 116956023
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 273 KB
Volume: 25
Category: Article
ISSN: 1078-1439
DOI: 10.1016/j.urolonc.2006.09.017

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase ii trial of oral estramustine an

A phase ii trial of oral estramustine and oral etoposide in hormone refractory prostate cancer

✍ Kenneth J. Pienta; Bruce G. Redman; Rajesh Bandekar; Myla Strawderman; Kemp Ceas 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 750 KB

Phase II Trial of Sunitinib for the Ther

Phase II Trial of Sunitinib for the Therapy of Progressive Metastatic Castration-Refractory Prostate Cancer After Previous Docetaxel Chemotherapy

✍ Guru Sonpavde; Thomas E. Hutson; William R. Berry; Kristi A. Boehm; Lina Asmar 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 93 KB

A phase II trial of dexamethasone, vitam

A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer

✍ Thomas W. Flaig; Albaha Barqawi; Gary Miller; Madeleine Kane; Chan Zeng; E. Davi 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 1 views

A Phase II Trial of Oral Trimethylcolchi

A Phase II Trial of Oral Trimethylcolchicinic Acid in Patients with Hormone Refractory Prostate Cancer

✍ Bruce E. Brockstein; Dale R. Shepard; John W. Kugler; Paul A. Fishkin; Rose Arri 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 207 KB

Combination of LHRH analog with somatost

Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study

✍ Meletios A. Dimopoulos; Christos Kiamouris; Dimitra Gika; Charalambos Deliveliot 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 117 KB

4005 ORAL An open label randomized Phase

4005 ORAL An open label randomized Phase II study of oral triple angiokinase inhibitor BIBF 1120 in Hormone Refractory Prostate Cancer (HRPC) patients who progressed after docetaxel

✍ S. Oudard; C. Chevreau; A. Fléchon; K. Gunzer; N. Houédé; I. Krakowski; H. de Mo 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB